文献速递妇科肿瘤

重新审视化疗不敏感卵巢癌的治疗强化:综述

Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer: A Review.
PubMed 文献 · JAMA Oncol · 2026-10-01

本综述聚焦晚期高级别浆液性卵巢癌中化疗反应不足、常无法完成完全肿瘤细胞减灭术的「双红旗」人群,探讨在维持治疗前进行系统治疗强化或化疗增敏的依据与策略。基于多项III期试验事后分析,周剂量密集紫杉醇和贝伐珠单抗在该亚组显示生存获益信号,而PARP抑制剂与免疫检查点抑制剂联合仅在特定亚组有活性。早期识别化疗不敏感患者并选择性强化治疗是正在前瞻性评估的应答适应策略。

要点

  • 化疗敏感性可用KELIM、病理化疗反应评分和影像学反应评估,已获指南引用。
  • 「双红旗」人群可能从周剂量密集紫杉醇或贝伐珠单抗强化中获益更多。
  • PARP抑制剂联合免疫检查点抑制剂仅在特定亚组显示有意义活性。

核心结论

  • 早期识别化疗不敏感的晚期高级别浆液性卵巢癌,可支持应答适应的一线策略,选择性给予治疗强化。

研究设计与样本

  • 本综述汇总多项III期试验(ICON-7、GOG-0218、ICON-8、ICON-8B、VELIA和IMagyn050)的事后分析,探讨系统治疗强化或化疗增敏策略。

主要发现

  • 在ICON-8的「双红旗」亚组中,周剂量密集紫杉醇与生存改善相关。
  • 贝伐珠单抗加入术后标准化疗或新辅助剂量密集化疗,在高危和化疗不敏感亚组中显示无进展生存和总生存获益信号。
  • PARP抑制剂与免疫检查点抑制剂联合仅在特定亚组显示有意义活性。

关键数值与推荐

  • KELIM、病理化疗反应评分和影像学反应是化疗敏感性的实用指标,已获ESMO-ESGO和ASCO指南引用。
  • BRCA/同源重组缺陷状态可能不能可靠预测新辅助卡铂-紫杉醇反应。

临床怎么用

  • 对化疗不敏感患者,可考虑周剂量密集紫杉醇或贝伐珠单抗强化治疗以提高反应和手术完全性。
  • PARP抑制剂联合免疫检查点抑制剂不宜在未经选择的化疗不敏感人群中常规使用。

局限性

  • 主要证据来自III期试验的事后分析,存在亚组分析固有局限性。
  • 化疗敏感性指标(KELIM、病理化疗反应评分、影像学反应)的预测价值需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite the integration of bevacizumab and poly(ADP-ribose) polymerase inhibitors into first-line treatment of advanced high-grade serous ovarian cancer, survival remains poor for the substantial subset of patients whose tumors respond insufficiently to platinum-based chemotherapy and who, therefore, frequently do not achieve complete cytoreductive surgery (the 2 red flags population). This Review examines the rationale, current evidence, and emerging strategies for systemic treatment intensification-or chemosensitization-aimed at improving tumor response before initiating maintenance therapy. OBSERVATIONS: Achieving minimal residual disease before maintenance depends on 2 key determinants: surgical completeness and intrinsic tumor chemosensitivity. Pragmatic indicators of chemosensitivity-KELIM (modeled cancer antigen 125 elimination rate constant K), pathological chemotherapy response score, and radiologic response-are now cited in European Society for Medical Oncology-European Society of Gynaecological Oncology and American Society of Clinical Oncology guidelines, while BRCA/homologous recombination deficiency status may not reliably predict neoadjuvant carboplatin-paclitaxel response. Across post hoc analyses of phase 3 trials (ICON-7, GOG-0218, ICON-8, ICON-8B, VELIA, and IMagyn050), patients with poorly chemosensitive disease may have derived greater benefit from intensification strategies. Weekly dose-dense paclitaxel was associated with improved survival in the 2 red flags subgroup of ICON-8. Bevacizumab, added either to standard postoperative chemotherapy or to neoadjuvant dose-dense chemotherapy, showed signals of greater benefit on both progression-free and overall survival in high-risk and poorly chemosensitive subsets. In contrast, poly(ADP-ribose) polymerase inhibitor and immune checkpoint inhibitor combinations showed meaningful activity only in selected subgroups, supporting further evaluation of innovative DNA repair-targeting agents and immunotherapeutic approaches in these populations. CONCLUSIONS AND RELEVANCE: Early identification of poorly chemosensitive advanced high-grade serous ovarian cancer enables a response-adapted first-line strategy in which treatment intensification is selectively offered to patients most likely to benefit-an approach now being prospectively evaluated in the phase 3 SALVOVAR and phase 1/2 RegeNovar trials. This framework provides a clinically actionable platform to test novel therapies aimed at increasing complete interval cytoreduction rates and improving survival in a population with otherwise limited options.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. You B, Clamp A, Moore KN, et al. Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer: A Review. JAMA Oncol. 2026. PMID: 42821287. doi:10.1001/jamaoncol.2026.3875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。